Quality of life in patients diagnosed with primary hepatocellular carcinoma: Hepatic arterial infusion of cisplatin versus 90-Yttrium microspheres (Therasphere®)

Jennifer Steel, Andrew Baum, Brian Carr

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background. The aims of the study were to test the difference in health-related quality (HRQL) of life and survival in patients diagnosed with primary hepatocellular carcinoma (HCC) and treated with either hepatic arterial infusion (HAI) of cisplatin or 90-Yttrium microspheres (Therasphere®). Method. The design of the study was a non-randomized parallel cohort study. Twenty-eight patients participated in the present study. HRQL was assessed by administration of the Functional Assessment of Cancer Therapy-Hepatobiliary. Survival was measured using Kaplan Meier methods. Results. The results of present study suggest treatment with Therasphere® had an advantage in regard to HRQL and survival when compared to cisplatin. At 3-month follow-up, patients who were treated with Therasphere® had a higher level of functional well-being as well as overall quality of life when compared to patients treated with cisplatin. At 6-month follow-up patients (treated with Therasphere®) continued to have better functional well-being when compared to patients being treated with HAI of cisplatin. At 6-month follow-up, survival was found to be similar for patients treated with Therasphere® when compared to patients being treated with cisplatin. Conclusions. Preliminary data suggest that treatment with Therasphere® has a modest advantage in regard to HRQL when compared patients treated with HAI of cisplatin. Future research with Therasphere®, that includes a larger sample size and longer follow-up, is necessary to make definitive conclusions regarding the efficacy and effect on HRQL.

Original languageEnglish
Pages (from-to)73-79
Number of pages7
JournalPsycho-Oncology
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2004

Fingerprint

Yttrium
Microspheres
Cisplatin
Hepatocellular Carcinoma
quality of life
Quality of Life
Liver
health
well-being
Survival
Health
cancer
Sample Size
Cohort Studies
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Psychology(all)
  • Social Sciences (miscellaneous)

Cite this

Quality of life in patients diagnosed with primary hepatocellular carcinoma : Hepatic arterial infusion of cisplatin versus 90-Yttrium microspheres (Therasphere®). / Steel, Jennifer; Baum, Andrew; Carr, Brian.

In: Psycho-Oncology, Vol. 13, No. 2, 02.2004, p. 73-79.

Research output: Contribution to journalArticle

@article{8bcaea9663df4932a4a161b9628cb248,
title = "Quality of life in patients diagnosed with primary hepatocellular carcinoma: Hepatic arterial infusion of cisplatin versus 90-Yttrium microspheres (Therasphere{\circledR})",
abstract = "Background. The aims of the study were to test the difference in health-related quality (HRQL) of life and survival in patients diagnosed with primary hepatocellular carcinoma (HCC) and treated with either hepatic arterial infusion (HAI) of cisplatin or 90-Yttrium microspheres (Therasphere{\circledR}). Method. The design of the study was a non-randomized parallel cohort study. Twenty-eight patients participated in the present study. HRQL was assessed by administration of the Functional Assessment of Cancer Therapy-Hepatobiliary. Survival was measured using Kaplan Meier methods. Results. The results of present study suggest treatment with Therasphere{\circledR} had an advantage in regard to HRQL and survival when compared to cisplatin. At 3-month follow-up, patients who were treated with Therasphere{\circledR} had a higher level of functional well-being as well as overall quality of life when compared to patients treated with cisplatin. At 6-month follow-up patients (treated with Therasphere{\circledR}) continued to have better functional well-being when compared to patients being treated with HAI of cisplatin. At 6-month follow-up, survival was found to be similar for patients treated with Therasphere{\circledR} when compared to patients being treated with cisplatin. Conclusions. Preliminary data suggest that treatment with Therasphere{\circledR} has a modest advantage in regard to HRQL when compared patients treated with HAI of cisplatin. Future research with Therasphere{\circledR}, that includes a larger sample size and longer follow-up, is necessary to make definitive conclusions regarding the efficacy and effect on HRQL.",
author = "Jennifer Steel and Andrew Baum and Brian Carr",
year = "2004",
month = "2",
doi = "10.1002/pon.725",
language = "English",
volume = "13",
pages = "73--79",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Quality of life in patients diagnosed with primary hepatocellular carcinoma

T2 - Hepatic arterial infusion of cisplatin versus 90-Yttrium microspheres (Therasphere®)

AU - Steel, Jennifer

AU - Baum, Andrew

AU - Carr, Brian

PY - 2004/2

Y1 - 2004/2

N2 - Background. The aims of the study were to test the difference in health-related quality (HRQL) of life and survival in patients diagnosed with primary hepatocellular carcinoma (HCC) and treated with either hepatic arterial infusion (HAI) of cisplatin or 90-Yttrium microspheres (Therasphere®). Method. The design of the study was a non-randomized parallel cohort study. Twenty-eight patients participated in the present study. HRQL was assessed by administration of the Functional Assessment of Cancer Therapy-Hepatobiliary. Survival was measured using Kaplan Meier methods. Results. The results of present study suggest treatment with Therasphere® had an advantage in regard to HRQL and survival when compared to cisplatin. At 3-month follow-up, patients who were treated with Therasphere® had a higher level of functional well-being as well as overall quality of life when compared to patients treated with cisplatin. At 6-month follow-up patients (treated with Therasphere®) continued to have better functional well-being when compared to patients being treated with HAI of cisplatin. At 6-month follow-up, survival was found to be similar for patients treated with Therasphere® when compared to patients being treated with cisplatin. Conclusions. Preliminary data suggest that treatment with Therasphere® has a modest advantage in regard to HRQL when compared patients treated with HAI of cisplatin. Future research with Therasphere®, that includes a larger sample size and longer follow-up, is necessary to make definitive conclusions regarding the efficacy and effect on HRQL.

AB - Background. The aims of the study were to test the difference in health-related quality (HRQL) of life and survival in patients diagnosed with primary hepatocellular carcinoma (HCC) and treated with either hepatic arterial infusion (HAI) of cisplatin or 90-Yttrium microspheres (Therasphere®). Method. The design of the study was a non-randomized parallel cohort study. Twenty-eight patients participated in the present study. HRQL was assessed by administration of the Functional Assessment of Cancer Therapy-Hepatobiliary. Survival was measured using Kaplan Meier methods. Results. The results of present study suggest treatment with Therasphere® had an advantage in regard to HRQL and survival when compared to cisplatin. At 3-month follow-up, patients who were treated with Therasphere® had a higher level of functional well-being as well as overall quality of life when compared to patients treated with cisplatin. At 6-month follow-up patients (treated with Therasphere®) continued to have better functional well-being when compared to patients being treated with HAI of cisplatin. At 6-month follow-up, survival was found to be similar for patients treated with Therasphere® when compared to patients being treated with cisplatin. Conclusions. Preliminary data suggest that treatment with Therasphere® has a modest advantage in regard to HRQL when compared patients treated with HAI of cisplatin. Future research with Therasphere®, that includes a larger sample size and longer follow-up, is necessary to make definitive conclusions regarding the efficacy and effect on HRQL.

UR - http://www.scopus.com/inward/record.url?scp=1242291142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242291142&partnerID=8YFLogxK

U2 - 10.1002/pon.725

DO - 10.1002/pon.725

M3 - Article

C2 - 14872525

AN - SCOPUS:1242291142

VL - 13

SP - 73

EP - 79

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 2

ER -